Primary cutaneous mucormycosis in a lung transplant recipient: case report and concise review of the literature.
Mucormycosis (zygomycosis) is an invasive, opportunistic fungal infection caused by organisms of the class Zygomycetes. Immunocompromised individuals, including both solid organ and hematopoietic stem cell transplant recipients, are preferentially affected. Among solid organ transplant (SOT) recipients, the sinuses, with or without involvement of the orbits and cerebrum, are the most common sites of disease, although the pulmonary allograft appears to be targeted following lung transplantation. Here, we describe the unique case of a lung transplant recipient who developed multifocal cutaneous mucormycosis without involvement of the pulmonary allograft, and review the published literature regarding incidence, treatment, and prognosis of primary cutaneous mucormycosis following SOT.
Page
A V
AV
Division of Infectious Diseases, University Health Network, University of Toronto, Toronto, Ontario, Canada.
Evans
A J
AJ
Snell
L
L
Liles
W C
WC
D000328:Adult; D000935:Antifungal Agents / Q000627:therapeutic use; D003646:Debridement; D003881:Dermatomycoses / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects*; D007166:Immunosuppressive Agents / Q000009:adverse effects; D016040:Lung Transplantation / Q000009:adverse effects*; D008297:Male; D009091:Mucormycosis / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology; D011183:Postoperative Complications / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology; D012233:Rhizopus / Q000302:isolation & purification*; D012829:Silicosis / Q000601:surgery*; D014230:Triazoles / Q000627:therapeutic use
D000935:Antifungal Agents; D007166:Immunosuppressive Agents; D014230:Triazoles; C101425:posaconazole